DJDa Som Jeon

Da Som Jeon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Da Som Jeon has a total of 52 co-authors. Here are the top co-authors by number of shared publications:

  • Chang-Min Choi

    Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea

    2 shared publications
  • Chaeuk Chung

    10Division of Pulmonology, Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Republic of Korea

    1 shared publication
  • Chaeuk Chung

    Department of Pulmonary and Critical Care Medicine, Chungnam National University Hospital, 282 Munhwa-ro, Jung-gu, Daejeon 35015, Republic of Korea

    1 shared publication
  • Chang Dong Yeo

    Division of Pulmonology, Department of Internal Medicine, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

    1 shared publication
  • Chang Dong Yeo

    Division of Pulmonary and Critical Care Medicine Department of Internal Medicine Eunpyeong St. Mary's Hospital College of Medicine The Catholic University of Korea Seoul Republic of Korea

    1 shared publication
  • Chang Hee Jung

    Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

    1 shared publication

Latest Publications

  • Diagnostic performance of the AptoDetect™-Lung biomarker for lung cancer in a high-risk Korean population: A multicenter prospective study

    by Dasom Jeon, Chang Dong Yeo, Chi Young Kim, Jung Seop Eom, Wonjun Ji, Min Jee Kim, Jung-Min Kim, Seong Hoon Yoon, June Hong Ahn, Jun Hyeok Lim, et al.

    Purpose: Blood-based biomarkers may improve risk stratification of indeterminate pulmonary nodules. We evaluated the diagnostic performance and independent predictive value of an aptamer-based blood assay in a high-risk Korean screening population. Methods: This multicenter prospective cohort study enrolled adults with Lung-RADS category 3 or 4 nodules detected on LDCT at ten tertiary hospitals in South Korea (June 2023–December 2024). Analyses focused on a predefined high-risk subgroup meeting Korean screening criteria (age 54–74 years, ≥30 pack-years). Baseline AptoDetect™-Lung scores were analyzed using multivariable logistic regression, and diagnostic performance was assessed by ROC analysis. Results: Among 1,084 participants with histopathologic confirmation, 319 met high-risk criteria, of whom 260 (81.5%) had lung cancer. In this subgroup, the AptoDetect™-Lung score was independently associated with malignancy (adjusted OR 1.14; 95% CI 1.02–1.27; p=0.020). Discrimination was higher in the high-risk subgroup than in the overall cohort (AUC 0.639 vs. 0.570; p=0.025). Performance was higher for squamous cell carcinoma and small cell lung cancer than for adenocarcinoma. A combined model including biomarker score, Lung-RADS category, age, and family history achieved an AUC of 0.710. Conclusions: An aptamer-based blood biomarker independently predicted lung cancer in high-risk individuals with LDCT-detected indeterminate nodules, supporting its adjunctive role in screening-based risk stratification. erj;68/suppl_70/PA1900/F1 F1 F1

  • Open Access

    Diagnostic Performance of the AptoDetect™-Lung Biomarker for Lung Cancer in a High-Risk Korean Population: A Multicenter Prospective Study

    by Da Som Jeon, Chang Dong Yeo, Chi Young Kim, Jung Seop Eom, Wonjun Ji, Min Jee Kim, Jung-Min Kim, Seong Hoon Yoon, June Hong Ahn, Jun Hyeok Lim, et al.

    Background/Objectives: Blood-based biomarkers may improve risk stratification of indeterminate pulmonary nodules detected on low-dose computed tomography (LDCT). We evaluated the diagnostic performance and independent predictive value of an aptamer-based blood assay, AptoDetect™-Lung, in a high-risk Korean screening population. Methods: This multicenter prospective cohort study enrolled adults with Lung Imaging Reporting and Data System (Lung-RADS) category 3 or 4 pulmonary nodules identified on LDCT across ten tertiary hospitals in South Korea between June 2023 and December 2024. Analyses focused on a predefined high-risk subgroup meeting Korean screening criteria (age 54–74 years and ≥30 pack-years of smoking). Baseline serum AptoDetect™-Lung scores were measured. Associations with lung cancer diagnosis were assessed using univariate and multivariable logistic regression, adjusting for clinical and radiologic variables. Diagnostic performance was evaluated using receiver operating characteristic analysis. Results: Among 1084 participants with histopathologic confirmation, 319 met high-risk criteria, of whom 260 (81.5%) were diagnosed with lung cancer. In this subgroup, the AptoDetect™-Lung score was independently associated with malignancy after adjustment (adjusted odds ratio of 1.14 per unit; 95% confidence interval of 1.02–1.27; p = 0.020). Discriminative performance was higher in the high-risk subgroup than in the overall cohort (area under the curve [AUC] of 0.639 vs. 0.570; p = 0.025). Performance was higher for squamous cell carcinoma and small-cell lung cancer than for adenocarcinoma. A multivariable model incorporating biomarker score, Lung-RADS category, age, and family history achieved an AUC of 0.710. Conclusions: An aptamer-based blood biomarker may provide modest adjunctive value for risk stratification in high-risk individuals.

  • Open Access

    Type 2 Diabetes Mellitus- and Complication-Related Risk of Nontuberculous Mycobacterial Disease in a South Korean Cohort

    by Da Som Jeon, Seonok Kim, Mi Ae Kim, Yong Pil Chong, Tae Sun Shim, Chang Hee Jung, Ye-Jee Kim, Kyung-Wook Jo

    We assessed whether patients with T2DM are at higher risk for incident NTM disease through analysis of NTM-naive matched cohorts from the data of a national population-based cohort which represents 2.2% of the total South Korean population. Although T2DM alone is not a statistically significant risk factor for NTM disease, T2DM significantly increases the risk of NTM disease in those with ≥2 diabetes-related complications.


  • Top Cited Papers
    Open Access

    Five-Year Overall Survival and Prognostic Factors in Patients with Lung Cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015

    by Da Som Jeon, Ho Cheol Kim, Se Hee Kim, Tae-Jung Kim, Hong Kwan Kim, Mi Hyung Moon, Kyongmin Sarah Beck, Yang-Gun Suh, Changhoon Song, Jin Seok Ahn, et al.

    Purpose This study aimed to provide the clinical characteristics, prognostic factors, and 5-year relative survival rates of lung cancer diagnosed in 2015.Materials and Methods The demographic risk factors of lung cancer were calculated using the KALC-R (Korean Association of Lung Cancer Registry) cohort in 2015, with survival follow-up until December 31, 2020. The 5-year relative survival rates were estimated using Ederer II methods, and the general population data used the death rate adjusted for sex and age published by the Korea Statistical Information Service from 2015 to 2020.Results We enrolled 2,657 patients with lung cancer who were diagnosed in South Korea in 2015. Of all patients, 2,098 (79.0%) were diagnosed with non–small cell lung cancer (NSCLC) and 345 (13.0%) were diagnosed with small cell lung cancer (SCLC), respectively. Old age, poor performance status, and advanced clinical stage were independent risk factors for both NSCLC and SCLC. In addition, the 5-year relative survival rate declined with advanced stage in both NSCLC (82%, 59%, 16%, 10% as the stage progressed) and SCLC (16%, 4% as the stage progressed). In patients with stage IV adenocarcinoma, the 5-year relative survival rate was higher in the presence of epidermal growth factor receptor (EGFR) mutation (19% vs. 11%) or anaplastic lymphoma kinase (ALK) translocation (38% vs. 11%).Conclusion In this Korean nationwide survey, the 5-year relative survival rates of NSCLC were 82% at stage I, 59% at stage II, 16% at stage III, and 10% at stage IV, and the 5-year relative survival rates of SCLC were 16% in cases with limited disease, and 4% in cases with extensive disease.